Millions of patients now take glucagon-like peptide-1 (GLP-1) receptor agonists, known as GLP-1 drugs, for type 2 diabetes and weight management.
November is National Diabetes Month, and World Diabetes Day falls on November 14.
That wide use has left three questions without firm answers: whether smaller doses could keep the benefits of GLP-1 drugs with fewer side effects, whether the drugs affect mental health, and whether they help women with polycystic ovary syndrome.
Three Cureus articles take up those questions, and News-Medical.Net covered all three between September 1 and November 1. This post gives the short version of each, then points to three more Cureus articles on GLP-1 drugs.
Microdosing means taking smaller, fractional doses of a GLP-1 drug to keep some of its benefit while easing side effects, cost, and shortages.
The review ties GLP-1 drugs to benefits beyond weight loss, including for the heart, kidneys, lungs, and thinking skills. Whether smaller doses keep those benefits is still unproven.
The article is a narrative review, so its search for studies was not systematic, and the authors urge caution and guidance from a licensed provider before anyone tries microdosing.
Read the News-Medical.Net story, “GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?”
Prefer the original? The review is “Multisystem Benefits of GLP-1 Microdosing: A Narrative Review,” by Mia A. Panlilio and colleagues, published in Cureus on July 30, 2026.
The exception was one large study of patients with obesity that found higher rates of depression, anxiety, and suicidal thoughts or attempts among those taking GLP-1 drugs.
The authors suggest that closer monitoring in weight-management clinics may explain part of the gap, but they did not test that idea.
Every study in the review was observational, so it can’t show that the drugs cause or prevent psychiatric problems.
Read the News-Medical.Net story, “GLP-1 drugs appear psychiatrically safe, but one finding still raises questions.”
Prefer the original? The review is “Impact of Glucagon-Like Peptide-1 Receptor Agonists on Mental Health: A Systematic Review of Psychiatric Safety and Antidepressant Potential,” by Aisha Quadir and colleagues, published in Cureus on September 3, 2026.
Androgens, hormones that are often elevated in PCOS, showed the most consistent change, and several studies also reported more regular periods.
Fertility is the open question. Some studies reported higher pregnancy rates when a GLP-1 drug was added to metformin, but far fewer studies looked at it.
Nearly all the studies also reported weight loss, so the review can’t show whether the reproductive changes came from the drugs or from weight loss.
Read the News-Medical.Net story, “Could GLP-1 drugs help women with PCOS beyond weight loss?”
Prefer the original? The review is “Reproductive and Gynecologic Effects of Glucagon-Like Peptide-1 Receptor Agonists in Women With Polycystic Ovary Syndrome: A Scoping Review,” by Jacklyn Snytte and colleagues, published in Cureus on September 28, 2026.
These Cureus articles cover additional related GLP-1 questions:
Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review. This review of 11 studies compares two widely used obesity drugs and includes one head-to-head randomized controlled trial.
Figure: Abdalla et al., Cureus, CC BY 4.0
Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors. This review of 38 studies compares GLP-1 drugs with another class of diabetes drugs on heart and kidney outcomes and finds that both classes lower risk, with different strengths.
Figure: Branigan et al., Cureus, CC BY 4.0
Efficacy and Safety of Oral Orforglipron for Weight Reduction in Adults With Overweight or Obesity: A Systematic Review. This review of six randomized controlled trials examines a GLP-1 medicine taken daily by mouth, including its common stomach-related side effects. All six trials were funded by Eli Lilly and Company.
Figure: Paredes Yacaman et al., Cureus, CC BY 4.0
This post was drafted with AI assistance and edited by our team before publishing.